The Global Biopharmaceutical CMO And CRO Market Growth Accelerated By Outsourcing Of Bioprocessing Needs
![]() |
Biopharmaceutical CMO And CRO |
The biopharmaceutical contract manufacturing (CMO) and
contract research organizations (CRO) provide services for manufacturing
biologics, vaccines, monoclonal antibodies, gene therapies and other
therapeutics for biopharmaceutical companies. The biopharmaceutical companies
outsource their needs for cell line development, protein expression and
purification for efficient development and manufacturing of biotherapeutics.
The global biopharmaceutical CMO and CRO Market is estimated
to be valued at US$ 41.71 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period
2024 to 2031, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The outsourcing trend among the biopharmaceutical companies is a major
driver of growth in the biopharmaceutical CMO and CRO market. As biotherapeutic
development involves complex bioprocessing steps, many smaller biopharma
companies lack required infrastructure and expertise for activities like
mammalian cell culture, purification and downstream processing. Larger
biopharma companies also find it more cost-effective to outsource non-core
activities to contract service providers. The CMOs and CROs provide flexible,
scalable solutions tailored to client's development and manufacturing needs. This
enables biopharma companies to focus on drug discovery and clinical development
while ensuring timely supply of biologics.
Segment Analysis
The biopharmaceutical CMO and CRO market is segmented on the basis of end
user, type and service. The service segment dominates the market as CMOs and
CROs offer various services to biopharma companies such as clinical trial
services, consulting services, manufacturing services, and non-clinical
services. Clinical trial services acquire the major share under service segment
owing to increasing clinical trials for biologics and biosimilars every year.
Key Takeaways
The global
biopharmaceutical CMO and CRO market analysis is expected to witness
high growth during the forecast period of 2024 to 2031. The global
biopharmaceutical CMO and CRO Market is estimated to be valued at US$ 41.71 Mn
in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024
to 2031.
Regional analysis shows that North America dominates the
market and is expected to continue its dominance during the forecast period.
This is due to presence of well-established CMOs, CROs and biopharma companies
in countries like US and Canada. Asia Pacific is expected to be the fastest
growing region mainly due to increasing investment by governments and companies
in pharmaceutical and biotechnology sector.
Key players operating in the biopharmaceutical CMO and CRO market are Albemarle
Corporation, Greenchemicals S.r.l., ICL, Jordan Bromine Company, Kingboard
Holdings Limited, LANXESS, Novel Chem, Shandong Brother Sci. & Tech. Co.,
Ltd., Shandong Futong Chemical Co., Ltd. and Tianjin Changlu Hangu Saltern Co.,
Ltd. Albemarle Corporation acquires majority share and is expanding its
manufacturing and service capabilities globally through acquisitions and collaborations
to strengthen its leadership position in the market.
Get more insights on
this topic: https://www.newswirestats.com/biopharmaceutical-cmo-and-cro-market-industry-insights-trends-biopharmaceutical-cmo-and-cro-market/
Comments
Post a Comment